Radbone: bone toxicity following pelvic radiotherapy – a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy

HIGHLIGHTS

• who: Victoria Chatzimavridou Grigoriadou u200d and collaborators from the Trial oversight An internal trial management group will be convened for the study, consisting of the chief investigator, project manager, Clinical Trials administrator, research nurse and a representative of the research and innovation division as core membersThe group will meet monthly. The study sponsor (Christie Hospital NHS Foundation Trust) will monitor the conduct of the trial. Author , Department of Endocrinology, The Christie Hospital NHS Foundation Trust, Manchester, UK , Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK , Department of Clinical Oncology, The Christie Hospital NHS Foundation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.